HS-10241
HS-10241 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
A Phase I Trial of HS-10241 in Solid Tumors
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors
Clinical Trials (6)
Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
A Phase I Trial of HS-10241 in Solid Tumors
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6